Appreciating the Potential of 3D Printing
Aprecia was actually founded in 2003 specifically to focus on – and unlock – the potential of 3D printing for pharmaceutical applications.
Stephanie Sutton |
Tom West, Project Director, Manager of Intellectual Property at Aprecia Pharmaceuticals, shares the story behind the company’s ZipDose Technology.
How did you find your focus?
When looking at all the different things that 3D printing could do for pharma, we tried to focus on what we thought would be a promising first area for commercial applicability. Fairly quickly, we realized that you don’t tend to see fast-melt applications for high-dose medicines (over 200 mg), despite all the established and successful technologies – at least not in the US, where the biggest cluster is actually for drugs under 50 mg. Clearly, there was a real opportunity to help patients that are struggling with larger tablets. We did some experiments in the lab and we found that 3D printing with our ZipDose platform can help produce high-dose formulation with rapid disintegration; the dose dissolves in seconds with a sip of liquid. This is the ZipDose formulation.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.